The influence of allogenic multipotent mesenchymal stromal cells of bone marrow on mortality and lifespan after extended hepatectomy: experimental study
Abstract
Multipotent mesenchymal stromal cells (MMSCs) can be a drug to prevent acute liver failure after extended hepatectomy. To evaluate the effectiveness of MMSCs it is necessary to conduct research on an adequate experimental model. Currently a universal model of acute liver failure does not exist. Mortality is observed after hepatectomy of >85% of the liver parenchyma. The volume of hepatectomy and anesthetic regime have an effect on mortality and lifespan.
The study was conducted in 36 male rats of Wistar breed. 1 rat was taken to obtain allogenic MMSCs of bone marrow. The study was divided into 2 parts. The first part is evaluation of the critical volume. This part includes two groups. In each group there were 14 rats with hepatectomy of 85 and 90%, respectively. In 7 rats in each group the anesthetic regime was Zoletil or Isoflurane. Second part is definition of influence the allogenic bone marrow MMSCs on survival. This part con- sists of 2 groups, 7 rats in each group. Control group was from the first part of study. Research group was with transplantation of 2.5 million allogenic MMSCs into inferior vena cava during operation. The volume of hepatectomy was established in part 1 of this work. The mortality and lifespan was assessed.
All animals after 85% hepatectomy survived regardless of the used anesthesia. All animals after 90% hepatectomy died at different times. Anesthetic regime influence on lifespan after 90% of hepatectomy. The mediana of lifespan was 12 hours and 48 hours with Zoletil and Isofluran respectively.
Transplantation of allogenic bone marrow MMSCs did not influence on mortality, after 90% hepatectomy (anesthesia Zoletil) all rats died in the first 2 days after surgery and the median of lifespan was 12 hours in two groups (p=0.66).
The volume of 90% of liver resection is critical, in which 100% of animals die. Anesthetic regime is effect on lifespan after 90% hepatectomy, but doesn't effect on mortality. The use of allogenic bone marrow MMSCs after 90% of hepatectomy doesn't effect on mortality and lifespan.
Keywords:extended hepatectomy, transplantation, multipotent mesenchymal stromal cells, inferior vena cava
For citation: Rudakov V.S., Astrelina T.A., Gubarev K.K., Zhurbin A.S., Svetlakova D.S., Voskanyan S.E. The influence of allogenic multipotent mesenchymal stromal cells of bone marrow on mortality and lifespan after extended hepatectomy: experimental study. Clin Experiment Surg. Petrovsky J. 2019; 7 (2): 31–7. doi: 10.24411/2308-1198-2019-12004. (in Russian)
Received 16.09.2017. Accepted 22.04.2019.
References
1. Voskanyan S.E., Artemiev A.I., Naydenov E.V., Zabezhinsky D.A., Chuchuev E.S., Rudakov V.S., Shabalin M.V., Shcherbin V.V. Transplantation technologies for surgical treatment of the locally advanced hepatic alveococcosis with invasion into great vessels. Annaly khirurgicheskoy gepatologii [Annals of Surgical Hepatology]. 2016; 21 (2): 25–32. (in Russian)
2. Rudakov V.S., Voskanyan S.E., Eremin I.I., Onnitsev I.E., Naidenov E.V., Eremin P.S., Zhgutov Yu.A. Multipotent stromal cells in the treatment of acute liver failure after extended hepatectomy in the experiment. Geny i kletki [Genes and Сells]. 2016; 11 (4): 90–100. (in Russian)
3. Kim E.F., Filin A.V., Semenkov A.V., Ushakova I.A., Burmistrov D.S., Metelin A.V., Khovrin V.V., Kryzhanovskaya E.Yu., Marchenko A.L., Varfolomeeva S.R., Kachanov D.Yu., Moiseenko R.A., Uskova N.G. Two-stage extended hepatic resection in patient with hepatoblastoma:first national experience. Clin Experiment Surg. Petrovsky J. 2013; 2: 28–35. (in Russian)
4. Voskanyan S.E., Naidyonov E.V., Artemyev A.I., Za- bezhinsky D.A., Rudakov V.S., Zhurbin A.S., Bashkov A.N., Grigorieva O.O. Comparative results of use liver protect- ing drugs for prophylaxis of the liver failure after extensive resections of the liver. Khirurgiya. Zhurnal imeni N.I. Pirogovа [Pirogov Russian Journal of Surgery. 2016; 9: 71–5. (in Russian)
5. Rudakov V.S., Voskanyan S.E., Eremin I.I., Deev R.V. Experimental models of acute liver failure. Rossiyskiy mediko-biologicheskiy vestnik im. akad. I.P. Pavlova [Russian Medical and Biological Bulletin named after acad. I.P. Pavlov. 2015; 4: 138–44. (in Russian)
6. Uribe-Cruz C., Kieling C.O., López M.L., Osvaldt A., et al. Encapsulated whole bone marrow cells improve survival in Wistar rats after 90% partial hepatectomy. Stem Cells Int. 2016; 7: 1–9.
7. Yu J., Yin S., Zhang W., Gao F., et al. Hypoxia preconditioned bone marrow mesenchymal stem cells promote liver regeneration in a rat massive hepatectomy model. Stem Cell Res Ther. 2013; 4: 83.
8. Kieling C.O., Backes A.N., Maurer R.L., Cruz C.U., et al. The effects of anesthetic regimen in 90% hepatectomy in rats. Acta Cir Bras. 2012; 27 (10): 702–6.
9. Matsuda M., Kato K., Mito M. [Effect of RES on liver regeneration and survival after 90% partial hepatectomy]. Nihon Geka Gakkai Zasshi. 1994; 95 (9): 662–8.
10. Liu Z.C., Chang T.M. Intrasplenic transplantation of bioencapsulated mesenchymal stem cells improves the recovery rates of 90% partial hepatatecromized rats. Stem Cells Int. 2012; 2012: 697094.
11. Miyazaki M., Hardjo M., Masaka T., Tomiyama K., et al. Isolation of a bone marrow-derived stem cell line with high proliferation; potential and its application for preventing acute fatal liver failure. Stem Cells. 2007; 25: 2855–63.
12. Sun X.E., Zhang X.Q., Liu M.M. Effect of bone marrow mesenchymal stem cells on the TGF-B1/Smad signaking pathway of hepatic stellate. Genet Mol Res. 2015; 14: 8744–54.
13. Gaub J., Iversen J. Rat liver regeneration after 90% partial hepatectomy. Hepatology. 1984; 4 (5): 902–4.
14. Yamamoto T., Navarro-Alvarez N., Soto-Gutierrez A., Yuasa T., et al. Treatment of acute liver failure in mice by hepatocyte xenotransplantation. Cell Transplant. 2010; 19 (6): 799–806.